StockData
Damora Therapeutics, Inc. logo

Damora Therapeutics, Inc. (DMRA) stock

DMRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$22.56+0.06 (+0.29%)

Close on Nov 17, 2026Market cap $1.39BP/E 5.7Yield 0.00%

Damora Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Damora Therapeutics's operating cash flow for the twelve months ending Sep 30, 2026 was -$59.13M. For fiscal 2025 it was -$6.73M. The highest annual figure on record is -$6.73M in fiscal 2025.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$6.73M–
FY2024Dec 31, 2024-$18.62M–
FY2023Dec 31, 2023-$36.91M–
FY2022Dec 31, 2022-$42.93M–
FY2021Dec 31, 2021-$52.31M–
FY2020Dec 31, 2020-$38.20M–
FY2019Dec 31, 2019-$19.33M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$17.23M–
Q2 FY2026Jun 30, 2026-$21.87M–
Q1 FY2026Mar 31, 2026-$20.60M–
Q4 FY2025Dec 31, 2025$566.00K–
Q3 FY2025Sep 30, 2025-$2.62M–
Q2 FY2025Jun 30, 2025-$2.24M–
Q1 FY2025Mar 31, 2025-$2.44M–
Q4 FY2024Dec 31, 2024-$4.94M–
Q3 FY2024Sep 30, 2024-$3.65M–
Q2 FY2024Jun 30, 2024-$4.10M–
Q1 FY2024Mar 31, 2024-$5.94M–
Q4 FY2023Dec 31, 2023-$11.47M–
Q3 FY2023Sep 30, 2023-$8.45M–
Q2 FY2023Jun 30, 2023-$7.85M–
Q1 FY2023Mar 31, 2023-$9.13M–
Q4 FY2022Dec 31, 2022-$11.45M–
Q3 FY2022Sep 30, 2022-$9.85M–
Q2 FY2022Jun 30, 2022-$14.84M–
Q1 FY2022Mar 31, 2022-$6.80M–
Q4 FY2021Dec 31, 2021-$17.83M–
Q3 FY2021Sep 30, 2021-$9.16M–
Q2 FY2021Jun 30, 2021-$11.17M–
Q1 FY2021Mar 31, 2021-$14.15M–
Q4 FY2020Dec 31, 2020-$14.52M–
Q3 FY2020Sep 30, 2020-$8.58M–
Q2 FY2020Jun 30, 2020-$7.13M–
Q1 FY2020Mar 31, 2020-$7.98M–
Q4 FY2019Dec 31, 2019-$5.25M–

More Damora Therapeutics figures

See a number that looks wrong?